Clinical effect of adding hMG to the follicular phase long protocol for standard group with normal ovarian reserve function
- Author:
- No author available
- Journal Title:
- Chinese Journal of Obstetrics and Gynecology
- Issue:
- 5
- DOI:
- 10.3760/cma.j.cn112141-20210327-00155
- Key Word:
- 生殖技术，辅助;促生育素类;卵泡期;临床方案;妊娠结局;Reproductive techniques, assisted;Menotropins;Follicular phase;Clinical protocol;Pregnancy outcome
Abstract： Objective:To investigate the impact of adding human menopausal gonadotropin (hMG) for in vitro fertilization-embryo transfer pregnancy outcomes in a standard population of non-advanced age with normal ovarian reserve function using a long follicular phase protocol.Methods:Clinical data of 489 patients with normal ovarian reserve function, who were admitted from January 2018 to January 2020 in the Affiliated Hospital of Guizhou Medical University and underwent in vitro fertilization for the first time with the long follicular phase protocol in fresh cycles, were retrospectively analyzed. The patients were divided into three groups according to whether or not to add urine-derived hMG and the timing of addition: non-addition group (group A), medium-term hMG group (group B1), whole course hMG group (group B2); the laboratory parameters of each group were observed, and the effect of ovulation induction drugs and pregnancy outcomes were compared.Results:The ages of B1 and B2 groups were significantly higher than that of group A ( P=0.019 and P=0.011). The basal FSH level of group B2 was significantly higher than those of group A and group B1 ( P<0.01 and P=0.006), and the basal FSH/LH ratio of group B2 was significantly higher than that of group B1 ( P=0.009). Antral follicle counts of group A and group B1 were significantly higher than that of group B2 ( P=0.007 and P=0.017). The superior embryo rate of group B2 [(47±27)%] was significantly higher than that of group A ( P=0.017). The embryo implantation rate of group B1 was significantly lower than those of group A and group B2 ( P=0.043 and P<0.01). The clinical pregnancy rate of group B2 [76.7% (155/202)] was significantly higher than those of group A ( P=0.039) and group B1 ( P<0.01). The live-birth rate of group B2 [67.3% (136/202)] was significantly higher than those of group A ( P=0.017) and group B1 ( P=0.001). Conclusions:For non-advanced aged patients with normal ovarian reserve function, the long protocol of follicular phase is suitable for those with relatively low ovarian reserve function. Adding hMG in the whole course of ovulation induction after gonadotropin-releasing hormone agonist reduction could improve the pregnancy outcomes by improving the quality of embryos.
- [1]徐士儒,李媛,刘红,等.重组人黄体生成素在体外受精-胚胎移植促排卵治疗中的应用[J].2010,(6).
- [2]王含必,温晓晓,汤鲜,等.低促性腺激素性性功能不全妇女IVF-ET治疗中的方法及疗效分析[J].2017,(5).
- [3]彭清妹,周志军,黄筱金.重组促黄体生成素与重组卵泡刺激素用于体外受精/卵胞质内单精子显微注射的Meta分析[J].2019,(10).
- [4]Driscoll G,Ryan J,Tyler J,etc.A relative reduction in mid-follicular LH concentrations during GnRH agonist IVF/ICSI cycles leads to lower live birth rates.[J].2006,21(10).
- [5]Takehara Y,Nadkarni PV,Chen HF,etc.Current opinion on use of luteinizing hormone supplementation in assisted reproduction therapy: an Asian perspective.[J].2011,23(1).
- [6]R, Fleming,C C, Chung,R W, Yates,etc.Purified urinary follicle stimulating hormone induces different hormone profiles compared with menotrophins, dependent upon the route of administration and endogenous luteinizing hormone activity.[J].1996,11(9).
- [7]Monique H, Mochtar,Nora A, Danhof,Reuben Olugbenga, Ayeleke,etc.Recombinant luteinizing hormone (rLH) and recombinant follicle stimulating hormone (rFSH) for ovarian stimulation in IVF/ICSI cycles.[J].2017,5(Spec ).
- [8]Weghofer A,Munne S,Brannath W.The impact of LH-containing gonadotropin stimulation on euploidy rates in preimplantation embryos: antagonist cycles.[J].2009,92(3).
- [9]Alviggi, Carlo,Conforti, Alessandro,Esteves, Sandro C.,etc.Recombinant luteinizing hormone supplementation in assisted reproductive technology: a systematic review[J].2018,109(4).
- [10]Crespo J,Pellicer A,Simon C,etc.Impact of luteinizing hormone administration on gonadotropin-releasing hormone antagonist cycles: an age-adjusted analysis.[J].2011,95(3).
- [11]Gottumukkala Achyuta Rama, Raju,Rahul, Chavan,Mamata, Deenadayal,etc.Luteinizing hormone and follicle stimulating hormone synergy: A review of role in controlled ovarian hyper-stimulation.[J].2013,6.
- [12]Laufer, Neri,Younis, Johnny S..Recombinant luteinizing hormone supplementation to recombinant follicle stimulating hormone therapy in gonadotropin releasing hormone analogue cycles: what is the evidence?[J].2018,34(5).
- [13]Smitz Johan,Platteau Peter.Influence of human chorionic gonadotrophin during ovarian stimulation: an overview[J].2020,18(1).
- [14]Hesham G, Al-Inany,Mohamed A, Youssef,Reuben Olugbenga, Ayeleke,etc.Gonadotrophin-releasing hormone antagonists for assisted reproductive technology.[J].2016.
- [15]乔杰,马彩虹,刘嘉茵,等.辅助生殖促排卵药物治疗专家共识[J].2015,(4).
- [16]Gizzo, Salvatore,Andrisani, Alessandra,Noventa, Marco,etc.Recombinant LH supplementation during IVF cycles with a GnRH-antagonist in estimated poor responders: A cross-matched pilot investigation of the optimal daily dose and timing[J].2015,12(3 Pt.B).
- [17]Levens,E.D.,Hill,M.J.,Levy,G..Does exogenous LH in ovarian stimulation improve assisted reproduction success? An appraisal of the literature[J].2012,24(3).
- [18]Palomino,W.A.,Argando?a,F.,Azúa,R.,etc.Complement C3 and decay-accelerating factor expression levels are modulated by human chorionic gonadotropin in endometrial compartments during the implantation window[J].2013,20(9).
- [19]Wu, Hsien-Ming,Chang, Hsun-Ming,Leung, Peter C. K..Gonadotropin-releasing hormone analogs: Mechanisms of action and clinical applications in female reproduction[J].2021,60.
- [20]Tal, Shavit,Mohammed, Agdi,Weon Y, Son,etc.A comparison between r-LH and urinary supplements containing LH activity in patients undergoing the microdose GnRH agonist flare protocol for in-vitro fertilization: a pilot study.[J].2016.
- [21]Ramaraju, G. A.,Cheemakurthi, Ravikrishna,Prathigudupu, Kavitha,etc.Role of Lh polymorphisms and r-hLh supplementation in GnRh agonist treated ART cycles: A cross sectional study[J].2018,222.